Insider Transactions in Q1 2021 at Syndax Pharmaceuticals Inc (SNDX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2021
|
Fabrice Egros |
SELL
Open market or private sale
|
Direct |
10,241
-19.6%
|
$245,784
$24.31 P/Share
|
|
Mar 01
2021
|
Fabrice Egros |
BUY
Exercise of conversion of derivative security
|
Direct |
10,241
+14.13%
|
$61,446
$6.78 P/Share
|
|
Feb 08
2021
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
35,156
-42.11%
|
$703,120
$20.55 P/Share
|
|
Feb 08
2021
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
35,156
+29.63%
|
$246,092
$7.2 P/Share
|
|
Feb 03
2021
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Fabrice Egros |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 03
2021
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
29,333
+50.0%
|
-
|
|
Feb 01
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-45.93%
|
$300,000
$20.19 P/Share
|
|
Feb 01
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+31.47%
|
$105,000
$7.2 P/Share
|
|
Jan 31
2021
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
1,771
+10.46%
|
$21,252
$12.0 P/Share
|
|
Jan 31
2021
|
Briggs Morrison |
BUY
Other acquisition or disposition
|
Direct |
1,771
+3.53%
|
$21,252
$12.0 P/Share
|